Separation and detection method for key intermediate and related impurities of Rurugolix

Through the HPLC method combined with the main component self-control method and gradient elution technology, the separation and content monitoring of key intermediates and impurities of Relugoli were successfully achieved, solving the problem that the existing technology could not effectively detect impurities, and improving Relugoli Quality control accuracy and purity of Goli products.

CN118980782AActive Publication Date: 2024-11-19HANGZHOU MINSHENG PHARM CO LTD

Patent Information

Application Number
CN202310523221.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-10
Publication Date
2024-11-19
Estimated Expiration
2043-05-10

AI Technical Summary

Technical Problem

The existing analytical methods cannot effectively detect the content of key intermediates and related impurities of Relugoli, making it difficult to monitor its quality and affect the purity of Relugoli products.

Method used

High performance liquid chromatography (HPLC) combined with the main components' self-control method, using octadecylsilane bonded silica gel as the stationary phase, and a mixture of phosphate buffer and acetonitrile as the mobile phase, gradient elution is carried out to achieve the R&D. Separation and content determination of key Lugoli intermediates and their impurities.

Benefits of technology

It significantly improves the quality control accuracy of Rellugoli products, ensures high purity production, high repeatability and precision of test results, excellent resolution, and meets drug quality research standards.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118980782A_ABST
    Figure CN118980782A_ABST
Patent Text Reader

Abstract

The invention discloses a method for separating and detecting a key intermediate and related impurities thereof, which adopts an HPLC (High Performance Liquid Chromatography) method and specifically comprises the following steps: preparing a test sample solution: taking a test sample and diluting to obtain the test sample solution; preparing a contrast solution, namely diluting the test solution; preparing a system-applicable solution, namely mixing the key intermediate and related impurities thereof, and diluting by using a diluent, so as to obtain the system-applicable solution; determining retention time: sampling the system applicable solution, carrying out HPLC (High Performance Liquid Chromatography) analysis, and determining the retention time; target substance detection: taking the test solution and the contrast solution for sample introduction, and carrying out separation detection; according to the method, octadecylsilane chemically bonded silica is taken as a filler and a stationary phase, a mixed solution of a phosphate buffer solution and acetonitrile is taken as a mobile phase A, acetonitrile is taken as a mobile phase B, and gradient elution is carried out. The method provided by the invention can realize separation and content determination of the key intermediate and related impurities thereof, and has good sensitivity, separation degree and repeatability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of liquid chromatography analysis, and in particular to a method for separating and detecting a key intermediate of relugolix and its related impurities. Background Art

[0002] Relugolix was originally developed by Takeda Pharmaceutical Co., Ltd., a small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist that can rapidly reduce female estrogen and progesterone. In January 2019, Relugolix was approved for marketing in Japan under the trade name It is used to improve the following symptoms caused by uterine fibroids: menorrhagia, lower abdominal pain, back pain and anemia. On December 18, 2020, the U.S. FDA approved relugoli for the treatment of adult patients with advanced prostate cancer under priority review.

[0003] Ethyl 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-(3-methoxyureido)phenyl)thiophene-3-carboxylate is a key intermediate of relugolix, and the quality control of this compound plays an important role in the preparation of relugolix API. At present, there are few reports on the analysis methods of key intermediates of relugolix. A preparation method of relugolix and its intermediates is disclosed in the application document with patent number CN115073490A, which records a method for detecting relugolix, using a Sunfire C8 chromatographic column, water (0.1% TFA) as mobile phase A, acetonitrile as mobile phase B, and gradient elution. However, this method is only used to detect the content of relugolix, and cannot detect the content of related impurities in the relugolix intermediates, which is not conducive to monitoring the quality of the relugolix intermediates.

[0004] In view of this, developing an efficient and accurate analytical method for key intermediates and related impurities of relugolix and achieving separation and purification of the intermediates are of great significance for the subsequent preparation of high-purity relugolix. Summary of the invention

[0005] In order to achieve efficient and accurate analysis, separation and purification of the key intermediates of relugolix and their related impurities, the present application provides a method for separating and detecting the key intermediates of relugolix and their related impurities.

[0006] The present application provides a method for separating and detecting a key intermediate of relugolix and its related impurities, which adopts HPLC method and specifically comprises the following steps: Prepare the test solution: dissolve the test sample in the diluent; Prepare control solution: take the test solution and dilute it with diluent; Prepare system suitability solution: Take the key intermediate of relugolix and its related impurities, mix them and dissolve them in a diluent; Determination of retention time: Take the system suitability solution for sampling and testing to determine the retention time of the key intermediate of relugolix and its impurities; Target substance separation and testing: Take the test solution and the control solution for sampling and testing, and calculate the content of impurities in the key intermediate of relugolix in the test solution by the main component self-control method; The HPLC method uses octadecylsilane bonded silica gel as the stationary phase, a mixed solution of phosphate buffer and acetonitrile as the mobile phase A, and acetonitrile as the mobile phase B, and performs gradient elution.

[0007] The key intermediate of relugolix described in the present application is 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-(3-methoxyureido)phenyl)thiophene-3-carboxylic acid ethyl ester, whose chemical formula is C 28 H 32 F2N4O6S, the structural formula is shown in formula (Ⅰ).

[0008] Formula (I) Preferably, the relevant impurities include: Impurity 03: 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-(3-methoxyureido)phenyl)thiophene-3-carboxylic acid; Impurity 01-E: 5-(4-aminophenyl)-2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)thiophene-3-carboxylic acid; Impurity 03-C: 2-((2,6-difluorobenzyl)amino)-4-((dimethylamino)methyl)-5-(4-(3-methoxyureido)phenyl)thiophene-3-carboxylic acid; Impurity 02-C: ethyl 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-ureidophenyl)thiophene-3-carboxylate; Impurity 01: 5-(4-aminophenyl)-2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)thiophene-3-carboxylic acid ethyl ester; Impurity 02-G: ethyl 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-methyl-5-(4-(3-methoxyureido)phenyl)thiophene-3-carboxylate.

[0009] The study found that the key intermediate (Formula I) of the present application is very similar to the impurity 03, impurity 01-E and structure. If the impurity is brought into the raw material drug during the preparation reaction of relugolix, it will be difficult to remove. Therefore, it is necessary to strictly monitor and separate the impurities in the preparation reaction of the key intermediate. This separation and detection method plays a vital role in the control of the relugolix synthesis reaction and the improvement of the quality, and directly affects the quality of the relugolix finished product. Specifically, in the HPLC analysis of the present application, while adopting the main component self-control method, a mixture of phosphate buffer and acetonitrile with different solubility for the key intermediate and each impurity is used as a mobile phase reagent, which can effectively achieve the separation and content determination of the key intermediate and its impurities during the gradient elution process, and effectively guarantee the quality of the relugolix product.

[0010] Preferably, in the system suitability solution, the concentration of the key intermediate is 1 mg / ml, and the concentrations of impurity 03, impurity 01-E, impurity 03-C, impurity 02-C, impurity 01, and impurity 02-G are all 5 μg / ml.

[0011] Preferably, the diluent is acetonitrile.

[0012] If the concentration of the test sample is too low, it is easy to cause insufficient signal strength, making separation and detection difficult, and reducing the accuracy and stability of the analysis. If the concentration of the test sample is too high, it is easy to cause instrument overload, affecting the separation effect and detection accuracy. The above range setting can avoid instrument overload while meeting the detection sensitivity requirements.

[0013] Preferably, the gradient elution is set as follows: Time (min) Mobile phase A (%) Mobile phase B (%) 0 75-80 20-25 18 60-65 35-40 30 33-38 62-67 35 33-38 62-67 38 75-80 20-25 45 75-80 20-25 Preferably, the gradient elution is set as follows: Time (min) Mobile phase A (%) Mobile phase B (%) 0 80 20 18 60 40 30 33 67 35 33 67 38 80 20 45 80 20 In the HPLC analysis of the present application, a reasonable gradient elution concentration is set according to the retention time measured by the system suitability solution, which significantly improves the sensitivity and separation of the method. Specifically, corresponding to the measured retention time, the present application continuously adjusts the amount of mobile phase A and mobile phase B in five intervals of 0-18min, 18-30min, 30-35min, 35-38min, and 38-45min during the elution process, and obtains the mobile phase matching ratio matched with the key intermediate, each related impurity polarity, and affinity, so that each component in the test solution is separated successively under the action of the mobile phase of different matching ratios, and the overlap of the elution time is low, and a gradient distribution can be presented on the chromatographic column. Finally, the accurate determination of the key intermediate and its related impurity content can be completed according to the obtained chromatogram.

[0014] Preferably, in the mobile phase A, the volume ratio of phosphate buffer to acetonitrile is 90:10.

[0015] Preferably, the phosphate buffer is selected from sodium dihydrogen phosphate buffer, disodium hydrogen phosphate buffer, potassium dihydrogen phosphate buffer, and dipotassium hydrogen phosphate buffer, and potassium dihydrogen phosphate buffer is more preferably used.

[0016] Preferably, the concentration of the phosphate buffer is 15-25 mmol / L; more preferably 20 mmol / L.

[0017] The mobile phase A of the present application adopts a mixed solution of phosphate buffer and acetonitrile to obtain a mobile phase that takes into account buffering capacity, solubility and elution properties, thereby improving the efficiency and accuracy of the separation and detection method.

[0018] Preferably, the flow rate of the mobile phase elution is 0.7-1.0 ml / min; more preferably 1.0 ml / min.

[0019] Preferably, in the HPLC analysis, the detection wavelength is 254±2 nm; more preferably 254 nm.

[0020] Preferably, the particle size of the octadecylsilane bonded silica gel as a filler is 2 to 5 μm, and the column temperature of the chromatographic column is 25 to 35°C.

[0021] Preferably, the particle size of the octadecylsilane bonded silica gel as a filler is 5 μm, and the column temperature of the chromatographic column is 30°C.

[0022] Preferably, the injection volume is 5-10 μl, more preferably 5 μl.

[0023] In summary, this application has the following beneficial effects: 1. This application effectively achieves the separation and content monitoring of key intermediates of relugolix and their related impurities by adopting the main component self-reference method, in combination with a specific mobile phase composition and gradient concentration setting, which plays an important role in improving the production quality of high-purity relugolix.

[0024] 2. The separation and detection method provided in this application has a high degree of separation between the key intermediate and impurity 03 and impurity 01-E, and the range of multiple measurement results is no higher than 0.01%. It has the advantages of strong specificity, high precision, good repeatability and good system applicability. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 This is the solution chromatogram of the system suitability of Example 1 of the present application.

[0026] Figure 2 This is the chromatogram of the mixed solution of Comparative Example 1 of the present application.

[0027] Figure 3This is the chromatogram of the mixed solution of Comparative Example 2 of the present application. DETAILED DESCRIPTION Example

[0028] Example 1, separation and detection method of key intermediates of relugolix and related impurities: 1. Chromatographic conditions: Chromatographic column: Kromasil 100-5C18, 250mm×4.6mm, 5μm; mobile phase A: 20mmol / L potassium dihydrogen phosphate buffer-acetonitrile (90:10), mobile phase B: acetonitrile, flow rate: 1.0ml / min; column temperature: 30℃, detection wavelength: 254nm, injection volume: 5μl. Gradient elution settings are as follows: 2. Separation and detection steps and test results Preparation of test solution: Take 10 mg of relugolix intermediate sample, place it in a 10 ml volumetric flask, add acetonitrile to dissolve and dilute to the scale to make a 1 mg / ml solution as the test solution.

[0029] Prepare control solution: take 1 ml of the test solution and place it in a 100 ml volumetric flask, dilute to the mark with acetonitrile to make a 10 μg / ml solution to obtain the control solution; Preparation of system suitability solution: Take appropriate amounts of the key intermediate of relugolix and impurities 03, 01-E, 03-C, 02-C, 01 and 02-G, accurately weigh them, place them in the same volumetric flask, add acetonitrile to dissolve and dilute to prepare a solution with a key intermediate concentration of 1 mg / ml and each related impurity concentration of 5 μg / ml, which is used as the system suitability solution.

[0030] Determination of retention time: Accurately measure 5 μl of the system suitability solution and inject it into the liquid chromatograph for HPLC analysis and record the chromatogram. Figure 1 It can be seen that in the system suitability solution, the separation degree of the key intermediate of relugolix and the adjacent impurity peak is 4.8, and the retention time is 18.002.

[0031] Target substance separation and detection: Accurately measure the above test solution and control solution and inject them separately, with the injection volume of 5ul, and perform HPLC analysis. Calculate the content of impurities in the key intermediate of relugolix in the test solution according to the main component self-reference method.

[0032] The test results show that the maximum range of the relevant impurity content detected in the 6 groups of test solutions is 0.01%, which is less than 0.02%.

[0033] Example 2, the separation and detection method of the key intermediate of relugolix and its related impurities, is different from that of Example 1 in that the chromatographic conditions are different, as follows: Chromatographic column: Kromasil 100-5C18, 250mm×4.6mm, 5μm; mobile phase A: 15mmol / L potassium dihydrogen phosphate buffer-acetonitrile (90:10), mobile phase B: acetonitrile, flow rate: 1.0ml / min; column temperature: 30℃, detection wavelength: 254nm, injection volume: 5μl. Gradient elution settings are as follows: Results of content test of key intermediates and related impurities in relugolix intermediates: The results showed that the maximum range of the relevant impurity content detected in the 6 groups of test solutions was 0.01%, which was less than 0.02%.

[0034] Conclusion: It can be seen from Examples 1 and 2 that under the chromatographic conditions of the present application, the key intermediate of relugolix and its related impurities can be completely separated. This method has strong specificity, high precision, good repeatability, and good system applicability. It meets the technical requirements of drug quality research standards, and the results obtained are stable and reliable.

[0035] Comparative Example Comparative Example 1 1. Chromatographic conditions: Chromatographic column: YMC-Pack-Pro C18, 150mm×4.6mm, 3μm; mobile phase A: 50mmol / L potassium dihydrogen phosphate buffer-acetonitrile (70:30), mobile phase B: acetonitrile, flow rate: 1.0ml / min; column temperature: 30℃, detection wavelength: 254nm, injection volume: 5μl. Gradient elution settings are as follows: 2. Separation and detection steps and test results Take appropriate amounts of impurity 03, impurity 01-E, impurity 02, impurity 02-C, impurity 02-G, and impurity 01, weigh them accurately, place them in the same volumetric bottle, add diluent to dissolve and dilute to make a mixed solution with a concentration of 20μg / ml for impurity 03, impurity 01-E, impurity 02, impurity 02-C, impurity 02-G, and impurity 01. Accurately measure 5μl and inject it into the liquid chromatograph. The chromatogram results are as follows: Figure 2 shown.

[0036] Conclusion: See Figure 2 It can be seen that under the chromatographic conditions, impurity 03 and impurity 01-E are not completely separated, which affects the quantitative results and qualitative judgment of impurities 03 and impurity 01-E.

[0037] Comparative Example 2 1. Chromatographic conditions: Chromatographic column: YMC-Pack-Pro C18, 150mm×4.6mm, 3μm; mobile phase A: 20mmol / L potassium dihydrogen phosphate buffer-acetonitrile (70:30), mobile phase B: acetonitrile, flow rate: 1.0ml / min; column temperature: 30℃, detection wavelength: 254nm, injection volume: 5μl. Gradient elution settings are as follows: 2. Separation and detection steps and test results Take appropriate amounts of impurity 03, impurity 01-E, impurity 02, impurity 02-C, impurity 02-G, and impurity 01, weigh them accurately, place them in the same volumetric bottle, add diluent to dissolve and dilute to make a mixed solution with a concentration of 20μg / ml for impurity 03, impurity 01-E, impurity 02, impurity 02-C, impurity 02-G, and impurity 01. Accurately measure 5μl and inject it into the liquid chromatograph. The chromatogram results are as follows: Figure 3 shown.

[0038] Conclusion: See Figure 3 It can be seen that under the chromatographic conditions, impurity 03 and impurity 01-E are not completely separated, which affects the quantitative results and qualitative judgment of impurities 03 and impurity 01-E.

[0039] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.

Claims

1. A method for separating and detecting a key intermediate of relugolix and its related impurities, characterized in that: The HPLC method is adopted, which specifically comprises the following steps: Prepare the test solution: dissolve the test sample in the diluent; Prepare control solution: take the test solution and dilute it with diluent; Prepare system suitability solution: Take the key intermediate of relugolix and its related impurities, mix them and dissolve them in a diluent; Determination of retention time: Take the system suitability solution for sampling and testing to determine the retention time of the key intermediate of relugolix and its impurities; Target substance separation and testing: Take the test solution and the control solution for sampling and testing, and calculate the content of impurities in the key intermediate of relugolix in the test solution by the main component self-control method; The HPLC method uses octadecylsilane bonded silica gel as the stationary phase, a mixed solution of phosphate buffer and acetonitrile as the mobile phase A, and acetonitrile as the mobile phase B for gradient elution.

2. The method for separating and detecting a key intermediate of relugolix and its related impurities according to claim 1, characterized in that: The relevant impurities include: Impurity 03: 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-(3-methoxyureido)phenyl)thiophene-3-carboxylic acid; Impurity 01-E: 5-(4-aminophenyl)-2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)thiophene-3-carboxylic acid; Impurity 03-C: 2-((2,6-difluorobenzyl)amino)-4-((dimethylamino)methyl)-5-(4-(3-methoxyureido)phenyl)thiophene-3-carboxylic acid; Impurity 02-C: ethyl 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-ureidophenyl)thiophene-3-carboxylate; Impurity 01: 5-(4-aminophenyl)-2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)thiophene-3-carboxylic acid ethyl ester; Impurity 02-G: ethyl 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-methyl-5-(4-(3-methoxyureido)phenyl)thiophene-3-carboxylate.

3. The method for separating and detecting a key intermediate of relugolix and its related impurities according to claim 1, characterized in that: The gradient elution was set up as follows: 0~18min: 75~80%A→60~65%A; 18~30min: 60~65%A→33~38%A; 30~35min: 33~38%A→33~38%A; 35~38min: 33~38%A→75~80%A; 38~45min: 75~80%A→75~80%A.

4. The method for separating and detecting a key intermediate of relugolix and its related impurities according to claim 1, characterized in that: The gradient elution was set up as follows: 0~18min: 80%A→60%A; 18~30min: 60%A→33%A; 30~35min: 33%A→33%A; 35~38min: 33%A→80%A; 38~45min: 80%A→80%A.

5. The method for separating and detecting a key intermediate of relugolix and its related impurities according to claim 1, characterized in that: In the mobile phase A, the volume ratio of phosphate buffer to acetonitrile is 90:

10.

6. The method for separating and detecting a key intermediate of relugolix and its related impurities according to claim 5, characterized in that: The phosphate buffer adopts potassium dihydrogen phosphate buffer.

7. The method for separating and detecting a key intermediate of relugolix and its related impurities according to claim 5, characterized in that: The concentration of the phosphate buffer is 15-25 mmol / L.

8. The method for separating and detecting a key intermediate of relugolix and its related impurities according to claim 4, characterized in that: The flow rate of the mobile phase elution is 0.7-1.0 ml / min.

9. The method for separating and detecting a key intermediate of relugolix and its related impurities according to claim 4, characterized in that: In the HPLC analysis, the detection wavelength was 254±2 nm.

10. The method for separating and detecting a key intermediate of relugolix and its related impurities according to claim 4, characterized in that: The particle size of the octadecylsilane bonded silica gel as a filler is 2-5 μm, and the column temperature of the chromatographic column is 25-35°C.

Citation Information

Patent Citations

  • Long-chain alkene double bond rapid on-line determination apparatus and application

    CN105628833A

  • High performance liquid chromatography detection method for empagliflozin intermediate and related substances thereof

    CN114264747A

  • Solid state forms of relugolix

    US20220227784A1

Cited By

  • Method for determining six genotoxic impurities in rerugolil by high performance liquid chromatography-mass spectrometry

    CN120064523A

  • Method for the determination of 6 genotoxic impurities in relugolix by high performance liquid chromatography - mass spectrometry

    CN120064523B